State Street Corporation filed a Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of 6,723,774 shares of Ironwood Pharmaceuticals Inc common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: State Street Corporation reported beneficial ownership of 6,723,774 shares of Ironwood Pharmaceuticals Inc common stock.
  • Percent of class: The reported stake represents 4.1% of the outstanding class of common stock.
  • Shared voting power: State Street disclosed shared power to vote or direct the vote of 6,516,093 shares, with sole voting power of 0.
  • Shared dispositive power: The filing reported shared power to dispose of 6,723,774 shares, with sole dispositive power of 0.
  • Subsidiaries involved: The shares were acquired through subsidiaries identified as SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, and State Street Global Advisors Trust Company, each classified as an investment adviser.
  • Event date: The date of the event requiring the filing was September 30, 2026.

State Street Corporation's Schedule 13G Disclosure for Ironwood Pharmaceuticals

State Street Corporation, organized in Massachusetts and headquartered at One Congress Street, Suite 1, Boston, MA 02114, filed a Schedule 13G with the Securities and Exchange Commission dated November 9, 2026, covering its holdings in Ironwood Pharmaceuticals Inc (CUSIP 46333X108). According to the filing, the event triggering the disclosure occurred on September 30, 2026. The filing identifies State Street Corporation as a parent holding company, with the type of reporting person designated as "HC."

The filing disclosed aggregate beneficial ownership of 6,723,774 shares of Ironwood Pharmaceuticals common stock, representing 4.1% of the class. State Street reported no sole voting power and no sole dispositive power over any of these shares. Shared voting power was reported over 6,516,093 shares, while shared dispositive power covered the full 6,723,774 shares. The filing noted ownership of 5 percent or less of the class under Item 5.

Three subsidiaries were identified under Item 7 as having acquired the securities on behalf of the parent: SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, and State Street Global Advisors Trust Company, each classified as an investment adviser. The filing certified, as required, that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The statement was signed by Alok Maheshwary, Senior Vice President, on November 9, 2026.

What Was Disclosed

State Street Corporation disclosed a 4.1% beneficial ownership position, totaling 6,723,774 shares of Ironwood Pharmaceuticals Inc common stock, held through three investment adviser subsidiaries as of September 30, 2026, with all voting and dispositive power shared rather than sole.